Loading
A phase 1/2 trial of Divarasib, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, now recruiting.
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation is a phase 1/2 interventional study registered as NCT05789082 by Hoffmann-La Roche, with 320 participants planned, started 2023-06-20 and due to reach its primary completion in 2032-01-29. Interventions recorded: Divarasib, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin.
Shares KRAS & RAS inhibitors, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.